CollPlant Biotechnologies announced on June 6, 2024, the successful 3D bioprinting of 200cc breast implants, which are considered commercial size. These implants were created using the company's proprietary rhCollagen-based bioinks, marking a significant development in its regenerative breast implant program.
The program aims to develop novel regenerative implants that offer an alternative to existing market options, which often carry risks of immunogenic reactions. The successful fabrication of commercial-sized implants is a critical milestone in preparing for future clinical development.
Currently, no commercial products exist that enable the regeneration of soft tissues such as the breast. CollPlant's achievement positions its platform as a potential breakthrough in this field, addressing a market opportunity estimated at $3 billion annually.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.